Table 3

Malignancies in patients on bDMARDs compared with patients on csDMARDs or general population (observational studies)

Embedded Image
  • Estimates in bold reflect a risk/ratio statistically significantly different from 1, ie association is statistically significant.

  • More details are found in online supplementary tables S32–S38.

  • *Milan refers the Milan Cancer Report and Varese to the Varese Cancer Registry database. These were the general population comparators used.

  • †Standardised incidence rates are reported, with the general population as the reference; SIR of 100 means no difference between incidence rates.

  • ‡n=2 cases.

  • ABA, abatacept; ADA, adalimumab; aHR, adjusted HR; ANA, anakinra; ARTIS, Swedish Biologics Register; BCC, basal cell carcinoma; bDMARDs, biological disease-modifying antirheumatic drugs; BIOBADASER, Spanish Biologics Register; BSRBR, British Society of Rheumatology Biologics Register; CORRONA, Consortium of Rheumatology Researchers of North America; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; ETA, etanercept; IFX, infliximab; LOHREN, Lombardy Rheumatology Network (Italian Biologics Register); MTX, methotrexate; NA, not available (not mentioned in the original article); NR, not reported; pts, patients; RABBIT, Rheumatoid Arthritis Observation of Biologic Therapy ( in German); RATIO, French Biologics Register; RTX, rituximab; SCC, squamous cell carcinoma; TNFi, tumour necrosis factor α inhibitor.